SEVAN SAGHERIAN: Open Payments
NPI 1790253300 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$981 in 11 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $263 · 2025 $981
Food & beverage: $981
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 2 | $220 |
| Insulet Corporation | 1 | $150 |
| CeQur Corporation | 1 | $150 |
| Abbott Laboratories | 1 | $133 |
| Lilly USA, LLC | 1 | $109 |
| Medtronic, Inc. | 1 | $102 |
| Tandem Diabetes Care, Inc. | 3 | $95 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
Products named: Ozempic, OMNIPOD, CeQur Simplicity, FREESTYLE LIBRE 3, MOUNJARO, MINIMED 780G, t:slim X2 Insulin Pump with Control-IQ, GVOKE HYPOPEN.
Industry payments across PA — which companies pay providers there.
